GT Biopharma

GTBP · NASDAQ

$7.31+$0.62 (+9.27%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.69

Latest news

NewsSep 15, 8:45 AM ETVandana Singh
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
Press releaseAug 14, 8:00 AM ETGlobe Newswire
GT Biopharma Reports Second Quarter 2026 Financial Results
Press releaseJul 6, 11:19 AM ETPRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
Press releaseJun 30, 9:00 AM ETPRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Press releaseJun 12, 8:10 AM ETGlobe Newswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Press releaseJun 8, 9:01 AM ETGlobe Newswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Press releaseJun 2, 9:02 AM ETPRNewswire
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
Press releaseJun 1, 8:00 AM ETGlobe Newswire
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
NewsJun 1, 7:31 AM ETVandana Singh
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
Press releaseMay 29, 9:00 AM ETPRNewswire
The $13 Million Company Teaching the Immune System to Hunt Cancer
Press releaseMay 19, 9:00 AM ETPRNewswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Press releaseMay 18, 2:22 PM ETPRNewswire
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Press releaseMay 15, 8:00 AM ETGlobe Newswire
GT Biopharma Reports First Quarter 2026 Financial Results
NewsMay 14, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
Press releaseMay 14, 10:55 AM ETGlobe Newswire
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
Press releaseMay 14, 9:15 AM ETGlobe Newswire
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
Press releaseMay 14, 9:00 AM ETPRNewswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
NewsMay 14, 8:16 AM ETVandana Singh
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
NewsMay 14, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsMay 11, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsFeb 12, 4:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsFeb 3, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseJan 16, 11:18 AM ETGlobe Newswire
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
Press releaseJan 16, 8:00 AM ETPRNewswire
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
NewsJan 15, 8:01 AM ETVandana Singh
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
Press releaseDec 24, 6:00 AM ETGlobe Newswire
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Press releaseDec 19, 7:55 AM ETPRNewswire
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Press releaseDec 19, 7:44 AM ETPRNewswire
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Press releaseDec 15, 10:54 AM ETGlobe Newswire
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
Press releaseDec 11, 10:17 AM ETPRNewswire
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Press releaseDec 11, 9:14 AM ETGlobe Newswire
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market
NewsDec 5, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseDec 4, 12:20 PM ETPRNewswire
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
NewsNov 21, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsNov 17, 12:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 17, 7:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsNov 17, 4:42 AM ETAvi Kapoor
Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma Reports Second Quarter 2026 Financial Results

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout

The $13 Million Company Teaching the Immune System to Hunt Cancer

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

GT Biopharma Reports First Quarter 2026 Financial Results

12 Health Care Stocks Moving In Thursday's Intraday Session

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market

12 Health Care Stocks Moving In Friday's After-Market Session

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket